Abstract
e23106 Background: Genetic testing to guide 1st-line treatment is recommended for advanced non-small cell lung cancer (aNSCLC), but is complicated by small biopsy specimens available to test increasing numbers of biomarkers. This study compared commercially-available genetic tests for aNSCLC and the investigational use Oncomine™ Dx Target Test next generation sequencing (NGS) assay. Methods: This retrospective analysis used data from a large commercial lab, which offered clinical single-gene tests (EGFR therascreen, ALK Vysis, BRAF cobas, laboratory developed tests [LDT] for ROS1, BRAF, KRAS, MET, RET, and FGFR1); and NGS LDT (Illumina NextSeq 500). The lab also conducted investigational use of Oncomine Dx Target Test assay (Ion Torrent PGM Dx) on archival tissue. Clinical test orders received September 2015 – October 2016 were included. Sample rejection, test initiation, success rates, slide consumption, testing time, and turnaround time (TAT) were assessed. Results: Clinically, 3,857 single-gene and 219 NGS LDT tests were ordered on 1,479 samples for 1,436 patients. A total of 169 Oncomine Dx Target Tests were conducted. Conclusions: Investigational use of Oncomine Dx Target Test at this laboratory showed higher rates of test initiation and successful completion while using less tissue compared to either single-gene testing for ≥4 biomarkers or NGS LDT. This early experience suggests Oncomine Dx Target Test may enable therapy selection with multiple biomarker testing on small tissue samples for more aNSCLC patients compared to current methods. [Table: see text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
